These people could not get a corona vaccine.
That has finally changed
For immunocompromised people the corona epidemic was particularly severe, and they could not even get a vaccine that would keep them from the severe consequences.
Last week that changed.
Here are all the details
Walla!
health
12/12/2021
Sunday, 12 December 2021, 13:06 Updated: 13:21
Share on Facebook
Share on WhatsApp
Share on Twitter
Share on Email
Share on general
Comments
Comments
In the video: Bennett at a cabinet meeting talks about the possibility of a fourth vaccine for at-risk populations (Walla system!)
The U.S. Food and Drug Administration (FDA) last week approved the Astraznica antibody Abuschild for populations with suppressed immune systems that failed to develop antibodies or for those suffering from severe side effects after receiving corona vaccines.
The permit is given to those aged 12 and over.
The Ministry of Health is currently negotiating to purchase the antibody.
More on Walla!
How can Corona vaccines be effective against the Omicron variant?
To the full article
Studies show that up to two percent of the population do not develop adequate immunity to the corona virus even after receiving three doses of vaccine.
The main populations that do not develop an adequate immune response include people with immune system failure or those whose immune system is weak, usually due to receiving immunosuppressive therapies such as organ transplant recipients, hematooncology patients, chemotherapy patients and the like.
There are also people who develop severe side effects from corona vaccines and cannot get the vaccines available today.
More on Walla!
Researchers have compared the efficacy of 9 corona vaccines.
This is what they discovered
People with this health problem are more immune to corona
Loan on better terms from the bank: up to NIS 100,000 and for any purpose
Abushald is actually a passive vaccine that combines two antibodies that bind to different sites in the virus and prevent its binding to the receptor found on the cells, thus preventing the virus from entering the cells and preventing its culture.
The antibodies in the vaccine have undergone a change that allows them to be in the bloodstream for six months, thus providing protection for the population with a weakened immune system who are unable to produce the antibodies themselves.
77% reduction in the rate of symptomatic coronary events.
Man receives corona vaccine (Photo: Reuven Castro)
The FDA approved the vaccine based on a three-stage clinical study conducted in the US, UK, Spain, Belgium and France and included about 5,200 participants. 6 months after receiving the antibody phase, an 83 percent reduction in the rate of symptomatic corona was observed.The vaccine is given by injection into the muscle at a dose of 300 mg.
Not just a vaccine, but also a medicine
Abuschild is used not only as a vaccine but as a medicine for corona patients with mild to moderate illness.
The Food and Drug Administration is expected to approve in the coming weeks the label of the drug as a drug for patients based on a study (Tackle) conducted at 96 sites around the world, which was attended by about 900 people with mild to moderate symptomatic disease.
According to the findings, the drug demonstrated an 88 percent reduction in the chance of deterioration or death among patients treated three days or less from the moment of diagnosis, and a 67 percent reduction among patients treated five days or less from the moment of diagnosis.
The drug is given by injection into the muscle at a dose of 600 mg.
health
news
Tags
Vaccine for corona
Corona